Die wichtigsten Arbeiten zu.....
Atazanavir (Reyataz®)
# 59LB ACTG 5202: Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in Treatment-naive HIV-infected Patients
Eric Daar*1, C Tierney2, M Fischl3, A Collier4, K Mollan2, C
Budhathoki2, C Godfrey5, N Jahed6, D Katzenstein7, P Sax8, and
ACTG A5202 Study Team
1Los Angeles Biomed Res Inst at Harbor-UCLA, Torrance, US; 2Harvard
Sch of Publ Hlth, Boston, MA, US; 3Univ of Miami Miller Sch of Med, FL, US; 4Harborview Med Ctr,
Univ of Washington, Seattle, US; 5Div of AIDS, NIH, Bethesda, MD, US; 6Social & Sci Systems,
Inc, Silver Spring, MD, US; 7Stanford Univ, CA, US; and 8Brigham and Women`s Hosp, Harvard Med
Sch, Boston, MA, US
#106LB Bone and Limb Fat Outcomes of ACTG A5224s, a Substudy of ACTG A5202: A Prospective, Randomized, Partially Blinded Phase III Trial of ABC/3TC or TDF/FTC with EFV or ATV/r for Initial Treatment of HIV-1 Infection
Grace McComsey*1, D Kitch2, E Daar3, C Tierney2, N Jahed4, P Tebas5, L Myers6, P Sax7, and AACTG Study A5224
1Case Western Reserve Univ, Cleveland, OH, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Los Angeles Biomed Res Inst
at Harbor-UCLA, Torrance, US; 4Social & Sci Systems, Inc, Silver Spring, MD, US; 5Univ of Pennsylvania,
Philadelphia, US; 6Frontier Sci and Tech Res Fndn, Amherst, NY, US; and 7Brigham and Women`s Hosp, Harvard Med Sch,
Boston, MA, US
#107LB Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study
Ole Kirk*1, A Mocroft2, P Reiss3, S De Wit4, D
Sedlacek5, M Beniowski6, J Gatell7, A Phillips2, B Ledergerber8,
J Lundgren1,9, and for the EuroSIDA Study Group
1Copenhagen HIV Prgm, Univ of Copenhagen,
Denmark; 2Royal Free and Univ Coll London Med Sch, UK; 3Academic Med Ctr, Univ of Amsterdam, The
Netherlands; 4Ctr Hosp Univ Saint-Pierre, Brussels, Belgium; 5Charles Univ Hosp, Plzen, Czech
Republic; 6Specialistic Hosp, Chorzow, Poland; 7Hosp Clin, Barcelona, Spain; 8Univ Hosp
Zurich, Switzerland; and 9Rigshospitalet, Copenhagen, Denmark
#907 Steady State Pharmacokinetic of Ritonavir-boosted Atazanavir in 31 Pregnant Women before and after Delivery.
D Ripamonti1, D Cattaneo2, A d’Avolio3, M Simiele3, S Bonora3, N Strobelt1, M Ruggeri1, E Bombana1, F
Maggiolo1, and Fredy Suter*1
1Hosp Riuniti de Bergamo, Italy; 2Hosp Luigi Sacco, Milan, Italy; and 3Hosp A di
Savoia, Turin, Italy
#58LB Single-tablet, Fixed-dose Regimen of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Achieves a High Rate of Virologic Suppression and GS-9350 Is an Effective Booster
Calvin Cohen*1, D Shamblaw2, P Ruane3, R Elion4, E DeJesus5, H Liu6, L Zhong6, D Warren6, B Kearney6,
and S Chuck6
1Community Res Initiative of New England, Boston, MA, US; 2San Diego, CA, US; 3Los Angeles, CA, US;
4Whitman Walker Clin, Washington, DC, US; 5Orlando Immunology Ctr, FL, US; and 6Gilead Sci, Foster City, CA, US
Kollegen Fragen
Diese Seite weiter empfehlen
